{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2011"],"condition":["colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2620339"],"location":["Japan"],"study_start_month":["1"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Cohort study of Patients with metastatic colorectal cancer Treated by XELOX with bevacizumab","description":"Interventions: 1)Capecitabine at a dose of 2,000mg/m2/day orally in 2 divided doses for 2weeks on and 1week rest 2) tri-Weekly oxaliplatin at a dose of 130mg/m2 intravenously 3) tri-weekly bevacizumab at a dose of 5mg/kg intravenously\nPrimary outcome(s): Frequency and Degree of Hand-foot symdrome(HFS),Neuropathy and Vascular disorders\nStudy Design: Single arm Non-randomized","dates":{"creation":"2011-01-15"},"accession":"2620339","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000004896"]}}